Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held virtually December 5-8, 2020.
Details of the presentations are as follows:
Abstract Number: 1690
Title: DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
Date: Sunday, December 6, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster II
Presenter: Vu Hong, PhD, Director and Project Leader
Abstract Number: 2599
Title: DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia
Date: Monday, December 7, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster III
Presenter: Maria Beconi, PhD, SVP of Translational Research and Development
Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/.
###
About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.
Media Contacts:
Arleen Goldenberg
agoldenberg@vergescientific.com
202.930.4762